In the latest trading session, 0.5 million Adaptive Biotechnologies Corp (NASDAQ:ADPT) shares changed hands as the company’s beta touched 1.46. With the company’s most recent per share price at $7.01 changing hands around $0.94 or 15.40% at last look, the market valuation stands at $1.03B. ADPT’s current price is a discount, trading about -6.42% off its 52-week high of $7.46. The share price had its 52-week low at $2.28, which suggests the last value was 67.48% up since then. When we look at Adaptive Biotechnologies Corp’s average trading volume, we note the 10-day average is 1.39 million shares, with the 3-month average coming to 1.23 million.
Analysts gave the Adaptive Biotechnologies Corp (ADPT) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended ADPT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Adaptive Biotechnologies Corp’s EPS for the current quarter is expected to be -0.24.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Instantly ADPT is in green as seen in intraday trades today. With action -1.34%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 16.85%, with the 5-day performance at -1.34% in the red. However, in the 30-day time frame, Adaptive Biotechnologies Corp (NASDAQ:ADPT) is 13.72% up. Looking at the short shares, we see there were 9.19 million shares sold at short interest cover period of 8.44 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 49.93% from its recent market value. According to analyst projections, ADPT’s forecast low is 5 with 18 as the target high. To hit the forecast high, the stock’s price needs a -156.78% plunge from its current level, while the stock would need to tank 28.67% for it to hit the projected low.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Data shows that the Adaptive Biotechnologies Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 57.42% over the past 6 months, a 18.84% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 4.34% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 46.15M. 7 analysts are of the opinion that Adaptive Biotechnologies Corp’s revenue for the current quarter will be 46.49M. The company’s revenue for the corresponding quarters a year ago was 45.78M and 41.87M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.80%. The estimates for the next quarter sales put growth at 11.03%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -32.91%. The 2025 estimates are for Adaptive Biotechnologies Corp earnings to increase by 28.53%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next quarterly earnings report in February.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.93% of Adaptive Biotechnologies Corp shares while 93.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.71%. There are 93.87% institutions holding the Adaptive Biotechnologies Corp stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 20.5736% of the shares, roughly 29.99 million ADPT shares worth $108.58 million.
RUBRIC CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.603% or 14.0 million shares worth $50.68 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. With 10.72 shares estimated at $74.08 million under it, the former controlled 7.26% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.84% of the shares, roughly 4.19 shares worth around $28.96 million.
